The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target

The current Coronavirus disease 2019 or COVID-19 pandemic has infected over two million people and resulted in the death of over one hundred thousand people at the time of writing this review. The disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Even though multiple vaccines and treatments are under development so far, the disease is only slowing down under extreme social distancing measures that are difficult to maintain. SARS-COV-2 is an enveloped virus that is surrounded by a lipid bilayer. Lipids are fundamental cell components that play various biological roles ranging from being a structural building block to a signaling molecule as well as a central energy store. The role lipids play in viral infection involves the fusion of the viral membrane to the host cell, viral replication, and viral endocytosis and exocytosis. Since lipids play a crucial function in the viral life cycle, we asked whether drugs targeting lipid metabolism, such as statins, can be utilized against SARS-CoV-2 and other viruses. In this review, we discuss the role of lipid metabolism in viral infection as well as the possibility of targeting lipid metabolism to interfere with the viral life cycle.

[1]  S. Caddy.  Developing a vaccine for covid-19 , 2020, BMJ.

[2]  G. Lawton.  Trials of BCG vaccine will test for covid-19 protection , 2020, New Scientist.

[3]  P. Hotez,et al.  COVID-19 vaccine design: the Janus face of immune enhancement , 2020, Nature Reviews Immunology.

[4]  Elisabeth Mahase.  Covid-19: What do we know so far about a vaccine? , 2020, BMJ.

[5]  Suh-Chin Wu.  Progress and Concept for COVID‐19 Vaccine Development , 2020, Biotechnology journal.

[6]  M. Banach,et al.  Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic , 2020, Archives of medical science : AMS.

[7]  Zacharias E. Andreadakis,et al.  The COVID-19 vaccine development landscape , 2020, Nature Reviews Drug Discovery.

[8]  P. Middleton,et al.  Ongoing Clinical Trials for the Management of the COVID-19 Pandemic , 2020, Trends in Pharmacological Sciences.

[9]  Jon Cohen,et al.  Vaccine designers take first shots at COVID-19. , 2020, Science.

[10]  R. Muniyappa,et al.  COVID-19 pandemic, coronaviruses, and diabetes mellitus , 2020, American journal of physiology. Endocrinology and metabolism.

[11]  J. Lechner-Scott,et al.  The COVID-19 pandemic and the use of MS disease-modifying therapies , 2020, Multiple Sclerosis and Related Disorders.

[12]  Mohammad Madjid,et al.  Potential Effects of Coronaviruses on the Cardiovascular System: A Review. , 2020, JAMA cardiology.

[13]  Tao Guo,et al.  Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[14]  T. Jones,et al.  Possible method for the production of a Covid-19 vaccine , 2020, Veterinary Record.

[15]  Peng Wu,et al.  Detection of Covid-19 in Children in Early January 2020 in Wuhan, China , 2020, The New England journal of medicine.

[16]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[17]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[18]  A. M. Leontovich,et al.  The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.

[19]  F. Carinci.  Covid-19: preparedness, decentralisation, and the hunt for patient zero , 2020, BMJ.

[20]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[21]  Haoran Guo,et al.  Methyl-β-cyclodextrin inhibits EV-D68 virus entry by perturbing the accumulation of virus particles and ICAM-5 in lipid rafts. , 2020, Antiviral research.

[22]  Sheng-Qun Deng,et al.  Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China , 2020, Journal of clinical medicine.

[23]  Tiantian Han,et al.  Coronavirus infections and immune responses , 2020, Journal of medical virology.

[24]  P. Horby,et al.  A novel coronavirus outbreak of global health concern , 2020, The Lancet.

[25]  K. To,et al.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.

[26]  Bisera Stepanovska,et al.  Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. , 2020, Pharmacological research.

[27]  T. Olsson,et al.  Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. , 2020, JAMA neurology.

[28]  C. Yip,et al.  Lipidomic Profiling Reveals Significant Perturbations of Intracellular Lipid Homeostasis in Enterovirus-Infected Cells , 2019, International journal of molecular sciences.

[29]  R. Chakinala,et al.  Sphingolipids in COPD , 2019, European Respiratory Review.

[30]  T. Hla,et al.  Sphingosine 1-phosphate: Lipid signaling in pathology and therapy , 2019, Science.

[31]  L. Hodson,et al.  The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state , 2019, Nature Reviews Endocrinology.

[32]  M. Marsh,et al.  Targeting viral entry as a strategy for broad-spectrum antivirals , 2019, F1000Research.

[33]  D. Sauter,et al.  Furin‐mediated protein processing in infectious diseases and cancer , 2019, Clinical & translational immunology.

[34]  M. Abu-Farha,et al.  Angiopoietin-like proteins in multiple sclerosis , 2019, Journal of Neuroimmunology.

[35]  Dong Yang,et al.  SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target , 2019, Nature Communications.

[36]  J. Pfeilschifter,et al.  Sphingolipid signaling in renal fibrosis. , 2018, Matrix biology : journal of the International Society for Matrix Biology.

[37]  Karin H. Frühwirth,et al.  Rhinovirus induces an anabolic reprogramming in host cell metabolism essential for viral replication , 2018, Proceedings of the National Academy of Sciences.

[38]  N. L. Le Novère,et al.  Host lipidome analysis during rhinovirus replication in HBECs identifies potential therapeutic targets[S] , 2018, Journal of Lipid Research.

[39]  R. Zeiser.  Immune modulatory effects of statins , 2018, Immunology.

[40]  Yusuf A. Hannun,et al.  Sphingolipids and their metabolism in physiology and disease , 2017, Nature Reviews Molecular Cell Biology.

[41]  A. Huwiler,et al.  The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives. , 2017, Pharmacology & therapeutics.

[42]  K. Irshad,et al.  Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection , 2017, World journal of hepatology.

[43]  B. Neuman,et al.  Inhibition of Cytosolic Phospholipase A2α Impairs an Early Step of Coronavirus Replication in Cell Culture , 2017, Journal of Virology.

[44]  Y. Li,et al.  Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection , 2017, Scientific Reports.

[45]  S. Batra,et al.  Unraveling the role of membrane microdomains during microbial infections , 2017, Cell Biology and Toxicology.

[46]  D. Herr,et al.  To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling. , 2016, Pharmacological research.

[47]  P. D. Nagy,et al.  Building Viral Replication Organelles: Close Encounters of the Membrane Types , 2016, PLoS pathogens.

[48]  J. Chan,et al.  Middle East respiratory syndrome coronavirus infection: virus-host cell interactions and implications on pathogenesis , 2015, Virology Journal.

[49]  T. Graeber,et al.  MYC-induced reprogramming of glutamine catabolism supports optimal virus replication , 2015, Nature Communications.

[50]  M. Gelb,et al.  Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome–CoV infection , 2015, The Journal of experimental medicine.

[51]  E. Méndez,et al.  Identification of Host Cell Factors Associated with Astrovirus Replication in Caco-2 Cells , 2015, Journal of Virology.

[52]  Susanna K. P. Lau,et al.  Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease , 2015, Clinical Microbiology Reviews.

[53]  P. D. Nagy,et al.  RNA virus replication depends on enrichment of phosphatidylethanolamine at replication sites in subcellular membranes , 2015, Proceedings of the National Academy of Sciences.

[54]  Ashutosh Kumar Singh,et al.  Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis , 2015, Neurology.

[55]  T. Bestebroer,et al.  Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture , 2014, Antimicrobial Agents and Chemotherapy.

[56]  T. Graeber,et al.  Adenovirus E4ORF1-induced MYC activation promotes host cell anabolic glucose metabolism and virus replication. , 2014, Cell metabolism.

[57]  J. Alwine,et al.  ChREBP, a glucose-responsive transcriptional factor, enhances glucose metabolism to support biosynthesis in human cytomegalovirus-infected cells , 2014, Proceedings of the National Academy of Sciences.

[58]  J. Pfeilschifter,et al.  Targeting the sphingosine kinase/sphingosine 1-phosphate pathway to treat chronic inflammatory kidney diseases. , 2014, Basic & clinical pharmacology & toxicology.

[59]  K. Baumstarck,et al.  Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. , 2013, JAMA.

[60]  S. Polyak,et al.  Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking. , 2013, Antiviral research.

[61]  S. Reddy,et al.  A Mechanistic Paradigm for Broad-Spectrum Antivirals that Target Virus-Cell Fusion , 2013, PLoS pathogens.

[62]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[63]  A. Komnos,et al.  Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: Open-label, randomized study* , 2011, Critical care medicine.

[64]  Hans-Georg Kräusslich,et al.  Role of lipids in virus replication. , 2011, Cold Spring Harbor perspectives in biology.

[65]  Jin Ye,et al.  Regulation of cholesterol and fatty acid synthesis. , 2011, Cold Spring Harbor perspectives in biology.

[66]  N. Heaton,et al.  Multifaceted roles for lipids in viral infection , 2011, Trends in Microbiology.

[67]  Liam Smeeth,et al.  Effect of statin treatment on short term mortality after pneumonia episode: cohort study , 2011, BMJ : British Medical Journal.

[68]  E. Gratton,et al.  Methyl-β-Cyclodextrins Preferentially Remove Cholesterol from the Liquid Disordered Phase in Giant Unilamellar Vesicles , 2011, The Journal of Membrane Biology.

[69]  C. Cameron,et al.  Viral Reorganization of the Secretory Pathway Generates Distinct Organelles for RNA Replication , 2010, Cell.

[70]  R. Doms,et al.  A Potent, Broad-Spectrum Antiviral Agent that Targets Viral Membranes , 2010, Viruses.

[71]  M. Jiang,et al.  Glycosphingolipids as Receptors for Non-Enveloped Viruses , 2010, Viruses.

[72]  Robert Damoiseaux,et al.  A broad-spectrum antiviral targeting entry of enveloped viruses , 2010, Proceedings of the National Academy of Sciences.

[73]  Qibin Zhang,et al.  Temporal Proteome and Lipidome Profiles Reveal Hepatitis C Virus-Associated Reprogramming of Hepatocellular Metabolism and Bioenergetics , 2010, PLoS pathogens.

[74]  Alex J Sutton,et al.  Statins for the prevention and treatment of infections: a systematic review and meta-analysis. , 2009, Archives of internal medicine.

[75]  J. Pfeilschifter,et al.  Lipids as targets for novel anti-inflammatory therapies. , 2009, Pharmacology & therapeutics.

[76]  Ari Helenius,et al.  Virus entry by macropinocytosis , 2009, Nature Cell Biology.

[77]  I. Clark,et al.  Minimising Influenza Disease with Fibrates , 2008 .

[78]  Abraham J Koster,et al.  SARS-Coronavirus Replication Is Supported by a Reticulovesicular Network of Modified Endoplasmic Reticulum , 2008, PLoS biology.

[79]  A. Huwiler,et al.  Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. , 2007, Critical reviews in oncology/hematology.

[80]  A. Huwiler,et al.  De novo ceramide biosynthesis is associated with resveratrol-induced inhibition of ornithine decarboxylase activity. , 2007, Biochemical pharmacology.

[81]  J. Pfeilschifter,et al.  Altering the sphingosine-1-phosphate/ceramide balance: a promising approach for tumor therapy. , 2006, Current pharmaceutical design.

[82]  Mark Marsh,et al.  Virus Entry: Open Sesame , 2006, Cell.

[83]  K. Nagashima,et al.  Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[84]  G. Gibbons.  Regulation of fatty acid and cholesterol synthesis: co-operation or competition? , 2003, Progress in lipid research.

[85]  D. Hardie,et al.  Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. , 2001, Biochemical Society transactions.

[86]  J. Pfeilschifter,et al.  Physiology and pathophysiology of sphingolipid metabolism and signaling. , 2000, Biochimica et biophysica acta.

[87]  Andrew Pekosz,et al.  Influenza Virus Assembly and Lipid Raft Microdomains: a Role for the Cytoplasmic Tails of the Spike Glycoproteins , 2000, Journal of Virology.

[88]  David H. L. Bishop,et al.  The International Committee on Taxonomy of Viruses , 1995 .

[89]  S. Wakil,et al.  Fatty acid synthesis and its regulation. , 1983, Annual review of biochemistry.